Patent intelligence · US
US 7173005
Insulin and IGF-1 receptor agonists and antagonists
Insulin and IGF-1 receptor agonists and antagonists
Patent details — US 7173005
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 6, 2007
- Expiration
- Feb 1, 2027
- Applicant
- ANTYRA INC.
- Claims
- 5
- CPC classes
- A61K, A61K38/08
Quick answer
US 7173005 (Insulin and IGF-1 receptor agonists and antagonists) is held by ANTYRA INC.. Status: granted. Granted Feb 6, 2007. Expires Feb 1, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ANTYRA INC.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K38/08
More from ANTYRA INC.
Related pharmaceutical patents in our USPTO index.
-
US 12290069
Pest control using natural pest control agent blends
granted -
US 12264149
Indazole compounds as kinase inhibitors
granted -
US 12071428
Indazole compounds as kinase inhibitors
granted -
US 12035713
Pest control using natural pest control agent blends
granted -
US 11896007
Pest control using natural pest control agent blends
granted -
US 11116214
Lice control composition and method
granted -
US 10881104
Arthropod control composition, formulation, and method
granted -
US 10799472
Antiparasitic compositions and methods
granted
Frequently asked questions
What is US patent 7173005?
US 7173005 (Insulin and IGF-1 receptor agonists and antagonists) is held by ANTYRA INC.. Status: granted. Granted Feb 6, 2007. Expires Feb 1, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7173005?
ANTYRA INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 7173005 expire?
Our index shows an expiration date of Feb 1, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.